Slide 1: Fourth Quarter 2016 Earnings Teleconference
Fourth Quarter 2016 Earnings Teleconference January 31, 2017
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations Fourth Quarter 2016 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candid
Slide 4: Opening Remarks
Opening Remarks Ian Read Chairman and Chief Executive Officer Fourth Quarter 2016 Earnings
Slide 5: CEO Perspectives
CEO Perspectives Another year of operational revenue growth in 2016, driven by both new and mature brands Pfizer Essential Health established itself as a leader in sterile injectables & biosimilars Pfizer Innovative Health performed well (Eliquis, Xeljanz, Chantix, Lyrica, Ibrance) Business
Slide 6: Financial Review
Financial Review Frank D’Amelio Executive Vice President & Chief Financial Officer Fourth Quarter 2016 Earnings
Slide 7: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) Fourth Quarter Full Year 2016 2015 Change 2016 2015 Change Revenues $13,627 $14,047 (3%) $52,824 $48,851 8% Reported Net Income/(Loss)(1) 775 (172) * 7,215 6,960 4% Reported EPS/(LPS)(1) 0.13 (0.03) * 1.17 1.11 5% Adj
Slide 8: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) Fourth Quarter 2016 2015 FX Impact Revenues $13,627 $14,047 ($228) (2%) Adjusted Cost of Sales(1) 3,046 2,983 (131) (4%) COS as a Percentage of Revenues 22.4% 21
Slide 9: 2016 Financial Guidance vs. Actual Results
2016 Financial Guidance(1)(2) vs. Actual Results Guidance Results Revenues $52.0 to $53.0 billion $52.8 billion Adjusted Cost of Sales(3) as a Percentage of Revenues 21.5% to 22.0% 22.0% Adjusted SI&A Expenses(3) $14.2 to $14.7 billion $14.7 billion Adjusted R&D Expenses(3) $7.8 to $8.1 billio
Slide 10: 2017 Financial Guidance
2017 Financial Guidance(1)(2) Revenues $52.0 to $54.0 billion Adjusted Cost of Sales(3) as a Percentage of Revenues 20.0% to 21.0% Adjusted SI&A Expenses(3) $13.7 to $14.7 billion Adjusted R&D Expenses(3) $7.5 to $8.0 billion Adjusted Other (Income) / Deductions(3) Approximately $100 million of dedu
Slide 11: Key Takeaways
Key Takeaways Finished full year 2016 with 5% operational revenue growth (excluding Hospira and Medivation), following 3% operational revenue growth in full year 2015 (excluding Hospira) Issued 2017 financial guidance Revenue guidance midpoint implies another year of mid-single-digit operational g
Slide 12: Q&A Session
Fourth Quarter 2016 Earnings Teleconference Q&A Session January 31, 2017
Slide 13: Appendix: Segment Financial Highlights
Appendix Segment Financial Highlights January 31, 2017
Slide 14: Pfizer Innovative Health Selected Financial Highlights
Pfizer Innovative Health Selected Financial Highlights ($ Millions, Except Percentages) Fourth Quarter Q4 2016 revenues increased 2% operationally to $7,726M vs. Q4 2015 % Change 2016 2015 Driven by Ibrance in the U.S., Eliquis globally, the Total Oper. addition of Xtandi in the U.S. as well as
Slide 15: Pfizer Essential Health Selected Financial Highlights
Pfizer Essential Health Selected Financial Highlights ($ Millions, Except Percentages) Fourth Quarter Q4 2016 revenues decreased 6% operationally to $5,902M vs. Q4 2015 % Change 2016 2015 Driven by operational declines in the Peri-LOE and Total Oper. Legacy Established Products portfolios, parti